172
Participants
Start Date
January 31, 2001
Primary Completion Date
March 31, 2004
Study Completion Date
April 30, 2011
Zoledronic Acid
Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
Risedronate
Oral risedronate 30 mg capsules.
Placebo to Risedronate
Oral placebo of risedronate capsules.
Placebo to Zoledronic Acid
5 mL of sterile water one dose intravenous infusion.
Calcium and Vitamin D
Calcium and vitamin D supplements were supplied.
Novartis Investigative Site, New York
Novartis investigative site, Syracuse
Novartis investigative site, Durham
Novartis Investigative Site, Miami
Novartis Investigative Site, Boca Raton
Novartis investigative site, Detroit
Novartis Investigative site, Maywood
Novartis Investigative Site, Lakewood
Novartis Investigative Site, Santa Monica
Novartis investigative site, Medford
Novartis investigative site, Worcester
Novartis investigative site, Providence
Novartis Investigative Site, Concord
Novartis Investigative Site, Fitzroy
Novartis Investigative site, Geelong
Novartis Investigative Site, Kogarah
Novartis Investigative site, Maroochydore
Novartis Investigative site, Nedlands
Novartis Investigative Site, Calgary
Novartis Investigative Site, London
Novartis Investigative Site, Montreal
Novartis Investigative Site, Ste-Foy
Novartis Investigative Site, Toronto
Novartis Investigative site, Auckland
Novartis Investigative Site, Christchurch
Novartis Investigative site, Salamanca
Novartis Investigative site, Liverpool
Novartis Investigative Site, Manchester
Novartis Investigative site, Nottingham
Novartis Investigative Site, Oxford
Novartis Investigative site, Penarth
Novartis investigative site, Pernarth
Novartis Investigative Site, Stanmore
Novartis Investigative Site, Vale of Glamorgan
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY